Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars
Scar Keloid
About this trial
This is an interventional treatment trial for Scar Keloid
Eligibility Criteria
Inclusion Criteria:
- Patient with clinically diagnosed keloid or hypertrophic scar
- Size of scar 1cm in length or more
- Informed consent given
Exclusion Criteria:
- Under treatment of keloids or hypertrophic scar in past 6 months
- Patient with renal disease
- Patient with liver disease
- History of Hypersensitivity to 5-fluorouracil or triamcinolone acetonide
- Immunosuppressed conditions: HIV, Immunosuppressive therapy, Uncontrolled diabetes
- Pregnant or lactating women or patient planning for pregnancy
- Open wound in the scar
- Atrophic scar
- Patients suffering from chronic infectious conditions like Tuberculosis
- Patients with low WBC count
Sites / Locations
- B.P. Koirala Institute of Health Sciences
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group A: Intralesional (IL) triamcinolone acetonide (TAC) alone;
Group B: Intralesional triamcinolone acetonide and 5-fluorouracil (5-FU) combination
Group A: 1 ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline. 5 units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units,covering an area of 0.5X0.5 cm2 of scar. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs( maximum dose=2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
Group B: 1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU. Injection Method: Five units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. (maximum dose 2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks), Post treatment follow up: at 12 weeks.